Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Should minimal residual disease negativity be the end point of myeloma therapy?

Literature DB >> 29296970

Should minimal residual disease negativity be the end point of myeloma therapy?

Abstract

Publisher's Note: This article has a companion Counterpoint by Sonneveld. Publisher's Note: Join in the discussion of these articles at Blood Advances Community Conversations.

Entities: Disease

Year: 2017 PMID： 29296970 PMCID： PMC5728451 DOI： 10.1182/bloodadvances.2016000117

Source DB: PubMed Journal: Blood Adv ISSN： 2473-9529

40 in total

Review 1. Multiple myeloma.

Authors: Antonio Palumbo; Kenneth Anderson
Journal: N Engl J Med Date: 2011-03-17 Impact factor: 91.245

2. Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation.

Authors: Sara Galimberti; Edoardo Benedetti; Fortunato Morabito; Federico Papineschi; Vincenzo Callea; Rita Fazzi; Caterina Stelitano; Francesca Andreazzoli; Francesca Guerrini; Elena Ciabatti; Massimo Martino; Francesco Nobile; Pasquale Iacopino; Mario Petrini
Journal: Leuk Res Date: 2005-08 Impact factor: 3.156

3. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.

Authors: Paul G Richardson; David S Siegel; Ravi Vij; Craig C Hofmeister; Rachid Baz; Sundar Jagannath; Christine Chen; Sagar Lonial; Andrzej Jakubowiak; Nizar Bahlis; Kevin Song; Andrew Belch; Noopur Raje; Chaim Shustik; Suzanne Lentzsch; Martha Lacy; Joseph Mikhael; Jeffrey Matous; David Vesole; Min Chen; Mohamed H Zaki; Christian Jacques; Zhinuan Yu; Kenneth C Anderson
Journal: Blood Date: 2014-01-13 Impact factor: 22.113

4. A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.

Authors: Paul G Richardson; Wanling Xie; Sundar Jagannath; Andrzej Jakubowiak; Sagar Lonial; Noopur S Raje; Melissa Alsina; Irene M Ghobrial; Robert L Schlossman; Nikhil C Munshi; Amitabha Mazumder; David H Vesole; Jonathan L Kaufman; Kathleen Colson; Mary McKenney; Laura E Lunde; John Feather; Michelle E Maglio; Diane Warren; Dixil Francis; Teru Hideshima; Robert Knight; Dixie-Lee Esseltine; Constantine S Mitsiades; Edie Weller; Kenneth C Anderson
Journal: Blood Date: 2014-01-15 Impact factor: 22.113

5. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.

Authors: Jesús F San-Miguel; Vânia T M Hungria; Sung-Soo Yoon; Meral Beksac; Meletios Athanasios Dimopoulos; Ashraf Elghandour; Wieslaw Wiktor Jedrzejczak; Andreas Günther; Thanyaphong Na Nakorn; Noppadol Siritanaratkul; Paolo Corradini; Suporn Chuncharunee; Je-Jung Lee; Robert L Schlossman; Tatiana Shelekhova; Kwee Yong; Daryl Tan; Tontanai Numbenjapon; Jamie D Cavenagh; Jian Hou; Richard LeBlanc; Hareth Nahi; Lugui Qiu; Hans Salwender; Stefano Pulini; Philippe Moreau; Krzysztof Warzocha; Darrell White; Joan Bladé; WenMing Chen; Javier de la Rubia; Peter Gimsing; Sagar Lonial; Jonathan L Kaufman; Enrique M Ocio; Ljupco Veskovski; Sang Kyun Sohn; Ming-Chung Wang; Jae Hoon Lee; Hermann Einsele; Monika Sopala; Claudia Corrado; Bourras-Rezki Bengoudifa; Florence Binlich; Paul G Richardson
Journal: Lancet Oncol Date: 2014-09-18 Impact factor: 41.316

6. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.

Authors: Antonio Palumbo; Hervé Avet-Loiseau; Stefania Oliva; Henk M Lokhorst; Hartmut Goldschmidt; Laura Rosinol; Paul Richardson; Simona Caltagirone; Juan José Lahuerta; Thierry Facon; Sara Bringhen; Francesca Gay; Michel Attal; Roberto Passera; Andrew Spencer; Massimo Offidani; Shaji Kumar; Pellegrino Musto; Sagar Lonial; Maria T Petrucci; Robert Z Orlowski; Elena Zamagni; Gareth Morgan; Meletios A Dimopoulos; Brian G M Durie; Kenneth C Anderson; Pieter Sonneveld; Jésus San Miguel; Michele Cavo; S Vincent Rajkumar; Philippe Moreau
Journal: J Clin Oncol Date: 2015-08-03 Impact factor: 44.544

Review 7. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.

Authors: Shaji Kumar; Bruno Paiva; Kenneth C Anderson; Brian Durie; Ola Landgren; Philippe Moreau; Nikhil Munshi; Sagar Lonial; Joan Bladé; Maria-Victoria Mateos; Meletios Dimopoulos; Efstathios Kastritis; Mario Boccadoro; Robert Orlowski; Hartmut Goldschmidt; Andrew Spencer; Jian Hou; Wee Joo Chng; Saad Z Usmani; Elena Zamagni; Kazuyuki Shimizu; Sundar Jagannath; Hans E Johnsen; Evangelos Terpos; Anthony Reiman; Robert A Kyle; Pieter Sonneveld; Paul G Richardson; Philip McCarthy; Heinz Ludwig; Wenming Chen; Michele Cavo; Jean-Luc Harousseau; Suzanne Lentzsch; Jens Hillengass; Antonio Palumbo; Alberto Orfao; S Vincent Rajkumar; Jesus San Miguel; Herve Avet-Loiseau
Journal: Lancet Oncol Date: 2016-08 Impact factor: 41.316

8. Lenalidomide after stem-cell transplantation for multiple myeloma.

Authors: Philip L McCarthy; Kouros Owzar; Craig C Hofmeister; David D Hurd; Hani Hassoun; Paul G Richardson; Sergio Giralt; Edward A Stadtmauer; Daniel J Weisdorf; Ravi Vij; Jan S Moreb; Natalie Scott Callander; Koen Van Besien; Teresa Gentile; Luis Isola; Richard T Maziarz; Don A Gabriel; Asad Bashey; Heather Landau; Thomas Martin; Muzaffar H Qazilbash; Denise Levitan; Brian McClune; Robert Schlossman; Vera Hars; John Postiglione; Chen Jiang; Elizabeth Bennett; Susan Barry; Linda Bressler; Michael Kelly; Michele Seiler; Cara Rosenbaum; Parameswaran Hari; Marcelo C Pasquini; Mary M Horowitz; Thomas C Shea; Steven M Devine; Kenneth C Anderson; Charles Linker
Journal: N Engl J Med Date: 2012-05-10 Impact factor: 91.245

9. Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis.

Authors: O Landgren; S Devlin; M Boulad; S Mailankody
Journal: Bone Marrow Transplant Date: 2016-09-05 Impact factor: 5.483

10. Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction.

Authors: Andy C Rawstron; Walter M Gregory; Ruth M de Tute; Faith E Davies; Sue E Bell; Mark T Drayson; Gordon Cook; Graham H Jackson; Gareth J Morgan; J Anthony Child; Roger G Owen
Journal: Blood Date: 2015-02-02 Impact factor: 22.113

6 in total

Review 1. Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma.

Authors: Hannah A Blair
Journal: Drugs Date: 2017-12 Impact factor: 9.546

2. Application of diffusion-weighted whole-body MRI for response monitoring in multiple myeloma after chemotherapy: a systematic review and meta-analysis.

Authors: Kaiwen Wang; Elsa Lee; Shedrack Kenis; Simon Hallam; Athar Haroon; Simon Wan; Neil Rabin; Antonio Rojas-Garcia; Anwar Padhani; Sola Adeleke
Journal: Eur Radiol Date: 2022-01-14 Impact factor: 7.034

3. Minimal residual disease negativity and lenalidomide maintenance therapy are associated with superior survival outcomes in multiple myeloma.

Authors: Dilan A Patel; Ragisha Gopalakrishnan; Brian G Engelhardt; Evonne McArthur; Salyka Sengsayadeth; Katie A Culos; Michael Byrne; Stacey Goodman; Bipin N Savani; Wichai Chinratanalab; Madan Jagasia; Claudio A Mosse; Robert F Cornell; Adetola A Kassim
Journal: Bone Marrow Transplant Date: 2020-01-28 Impact factor: 5.483

Review 4. Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T.

Authors: Dok Hyun Yoon; Mark J Osborn; Jakub Tolar; Chong Jai Kim
Journal: Int J Mol Sci Date: 2018-01-24 Impact factor: 5.923

5. Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma.

Authors: L Rasche; D Alapat; M Kumar; G Gershner; J McDonald; C P Wardell; R Samant; R Van Hemert; J Epstein; A F Williams; S Thanendrarajan; C Schinke; M Bauer; C Ashby; R G Tytarenko; F van Rhee; B A Walker; M Zangari; B Barlogie; F E Davies; G J Morgan; N Weinhold
Journal: Leukemia Date: 2018-12-20 Impact factor: 11.528

Review 6. Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives.

Authors: Alessandra Romano; Giuseppe Alberto Palumbo; Nunziatina Laura Parrinello; Concetta Conticello; Marina Martello; Carolina Terragna
Journal: Front Oncol Date: 2019-08-20 Impact factor: 6.244

6 in total